DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 9, 2006--Elan Corporation, plc today announced that it has agreed to sell the rights to Prialt(TM) (ziconotide, non-opioid severe chronic pain agent) in Europe ...

Charlie Weston ELAN said yesterday it had agreed to sell marketing rights for its Prialt painkiller in Europe to Japan's Eisai company for up to $100m in cash. Under the deal, Elan is set to receive ...

Dublin, Ireland - November 18, 2004 - Elan Corporation, plc today announced that PRIALT(tm) (ziconotide) has received a positive recommendation from the European Committee for Medicinal Products for ...

A deal with Eisai for severe painkiller Prialt may not be the pharmaceutical company's best move. On the surface, Elan did OK. It will receive as much as $100 million for the drug, for which it ...

Elan has won US regulatory approval for Prialt, its treatment for severe chronic pain. The company said the drug won approval from the US Food and Drug Administration for use in an infusion system ...

Prialt's success injects positive vibe amid asset sales. Elan (NYSE:ELN) investors are feeling happy these days, as the company continues its rebound from potential disaster. Yesterday, the Irish drug ...

NEW YORK (CBS.MW) -- Elan ELN, shares added more than 4 percent to $7.39 after Irish pharmaceutical firm said a phase III trial for its Prialt treatment for chronic pain met its primary endpoint. The ...

Biotechnology company Elan has agreed to sell marketing rights for its Prialt painkiller in Europe to Japan's Eisai company for up to $100m in cash. Under the deal, Elan is set to receive $50m when ...

Ireland’s Elan Corporation has received some good news from the European Commission, which has granted marketing approval for Prialt (ziconotide) for the treatment of severe, chronic pain in patients ...

March 11 (Reuters) - Privately held Azur Pharma Limited entered into a definitive agreement with Elan Pharmaceuticals Inc, a unit of Elan Corp , to buy its painkiller Prialt. Azur expects the deal to ...

New York, Aug 11 (Reuters) - An activist Elan Corp Plc investor is raising new questions over a potentially serious conflict of interest involving the sale of an Elan pain drug for a bargain basement ...

Elan is facing questions from activist investor Ib Sonderby about the cut-rate sale price for U.S. rights to the pain drug Prialt, which went to Azur Pharma International for $14.6 million. Apparently ...